<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01228266</url>
  </required_header>
  <id_info>
    <org_study_id>CMM-EM</org_study_id>
    <nct_id>NCT01228266</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Transplantation in MS</brief_title>
  <acronym>CMM-EM</acronym>
  <official_title>Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Saiz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <authority>Spain: Agencia Espa√±ola del Medicamento y Productos Sanitarios (AEMPS)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized Phase II study, masked and crossed-over with placebo to evaluate
      the safety and tolerability of autologous mesenchymal stem cell transplantation in patients
      with active multiple sclerosis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Crossover Assignment, Masking:  Double Blind (Subject, Investigator), Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of autologous mesenchymal stem cell</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate effects on MS disease activity measured by: clinical variables, MRI, OCT, immunological analysis and quality of life scales</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>autologous mesenchymal stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs suspension media. The treatment will be reversed at 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous mesenchymal stem cells</intervention_name>
    <description>A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS</description>
    <arm_group_label>autologous mesenchymal stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Inflammatory forms of MS

               1. Relapsing-remitting MS (RRMS) patients

               2. Secondary progressive MS (SPMS) patients with continued relapses

               3. Primary progressive MS (PPMS) patients with enhancing MRI lesions and positive
                  CSF (oligoclonal banding)

          2. Age 18-50 years

          3. Disease duration &gt;= 2 and &gt;= 10 years

          4. EDSS 3.0 - 6.5

          5. Progression, continued relapses or worsening MRI after at least a year of attempted
             therapy evidenced by:

               1. Increase of &gt;= 1 EDSS point (if baseline EDSS &lt;= 5.0) or 0.5 EDSS points (if
                  baseline EDSS &gt;= 5.5), or quantifiable, objective evidence of equivalent
                  progression

               2. &gt;= 1 moderate-severe relapses in past 18 months

               3. &gt;= 1 Gadolinium enhancing lesions (double or triple dose Gadolinium)

               4. &gt;= 1 new T2 lesion

               5. For PPMS only, &gt;= 1 Gadolinium enhancing lesions

          6. Has given informed consent to participate in the study.

        Exclusion Criteria:

          1. SPMS without ongoing relapses

          2. PPMS without positive CSF or Gadolinium enhancing lesions

          3. &lt;= 3 months since treatment with any immunosuppressive therapy

          4. &lt;=1 month since last treatment with interferon-B or glatiramer acetate

          5. Corticosteroid treatment &lt;= 30 days

          6. Relapse &lt;= 60 days

          7. History of cancer or clinical or laboratory results indicative of severe systemic
             diseases, including infection for HIV, Hepatitis B or C

          8. Any metallic or electronic device that precludes from undergoing MRI

          9. Pregnancy or lactation

         10. Current treatment with an investigational therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Saiz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic de Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Albert Saiz, MD</last_name>
    <phone>34932275414</phone>
    <email>asaiz@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurology Service, Hospital Clinic de barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Saiz, MD</last_name>
      <phone>34932275414</phone>
      <email>asaiz@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Albert Saiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <lastchanged_date>September 13, 2011</lastchanged_date>
  <firstreceived_date>October 25, 2010</firstreceived_date>
  <responsible_party>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
</clinical_study>
